Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Vericel (VCEL) stock in plain English

Free brief · no signupStart here
VCELPublished Nov 15, 2026
Vericel Corp
Healthcare · Biotechnology
Harvests patient cells to manufacture custom cartilage implants and severe burn treatments.
Assets:
Burlington facilityAdvanced manufacturing plant for cellular therapy production
MACI implantProprietary autologous cartilage repair product line
Epicel graftCustom grown skin grafts for extensive burn victims
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

79
OPS ScoreOperating finances
Latest quote
-0.66%$58.26
$2.97B
92.2×
$324.21M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 15, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was VCEL. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Vericel (VCEL) do?

Vericel Corp (VCEL) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Harvests patient cells to manufacture custom cartilage implants and severe burn treatments. Manufactures custom cell therapies for knee cartilage repair and severe burns using patient tissues. It is worth $2.97B on the market and sold $324.21M over the last year.

Market cap
$2.97B
P/E ratio
92.2×
Annual sales
$324.21M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 15, 2026

Brands and businesses behind VCEL

  • MACI: An autologous cellular implant that repairs knee cartilage damage, generating revenue per patient surgical procedure.
  • Epicel: A personalized cultured skin graft that treats severe deep dermal burns, sold directly to specialized burn centers.
  • NexoBrid: A topically applied enzyme biologic that removes dead tissue from severe burns, earning through hospital sales.

VCEL’s flags, in plain English

Each flag is a number from Vericel’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 15, 2026.

Stupid Cash

Can pay this year's bills 5.1 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Wide Gross Margin

Gross margin of 74.5% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Earnings Jumping

Profits up 137.2% this year. Profit per share is growing fast this year. One year does not make a trend, so check whether sales grew too.

Priced for Perfection

Priced at 92.2 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about VCEL

How big is Vericel?

Vericel’s market cap is $2.97B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $324.21M: what customers paid the company over the last year, before any costs.

What is VCEL’s P/E ratio?

VCEL’s P/E ratio is 92.2×. Investors pay about 92.2 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with VCEL?

Revenue depends heavily on commercial health insurers and government programs agreeing to pay for high-cost custom cell therapies. That is one risk on Vericel’s card. Its first risk flag is Priced for Perfection, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Vericel’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. VCEL’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card